（编辑 任世碧） 证券日报网讯 12月17日晚间，海森药业发布公告称，为规范公司募集资金管理，保护投资者权益，根 据相关规定，公司在中国银行东阳支行营业部（简称"开户银行"）开设募集资金专项账户（简称"专 户"），并与开户银行、保荐人中信证券股份有限公司签订《募集资金专户存储三方监管协议》。 ...

金专用账户开立、募集资金监管协议签署等相关事项。具体内容详见公司于 2025 年 10 月 31 日在巨潮资讯网(www.cninfo.com.cn)上披露的《关于部分募投项目结 项并将节余募集资金投入新项目的公告》（公告编号：2025-055）。 证券代码：001367 证券简称：海森药业 公告编号：2025-063 浙江海森药业股份有限公司 关于签订募集资金专户存储三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江海森药业股份有限公司首次 公开发行股票注册的批复》(证监许可〔2023〕588号)同意注册，并经深圳证 券交易所同意，公司首次向社会公开发行人民币普通股1,700.00万股，发行价格 44.48元/股，募集资金总额人民币75,616.00万元，扣除相关发行费用后实际募集 资金净额人民币67,571.85万元。上述资金于2023年4月3日全部到位，已经立信会 计师事务所（特殊普通合伙）出具的《验资报告》（信会师报字[2023]第ZF10312 号）予以验证。公司对募集资金 ...

证券日报网讯12月16日，海森药业（001367）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数约为1.1万户。 ...

Core Viewpoint - Haosen Pharmaceutical has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which enhances its brand recognition and industry influence, positively impacting its overall development [1][2]. Group 1: Recognition and Impact - The company was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021 and has now achieved national-level recognition [1]. - This recognition by the Ministry of Industry and Information Technology acknowledges the company's technological level, innovation capability, manufacturing quality, and overall strength [1]. Group 2: Research and Development - In the first three quarters of 2025, the company invested a total of 28.1661 million yuan in research and development, representing a year-on-year increase of 57.96% [1]. - The company is pursuing a multi-channel and diversified approach to convert research outcomes into market value through collaborations with research enterprises and universities [1]. Group 3: Product Pipeline - As of June 30, 2025, the company has 17 products under research, including APIs, intermediates, and formulations, targeting various therapeutic areas such as antiviral, antidepressant, lipid-lowering, non-steroidal anti-inflammatory, anti-rheumatic, and anti-ulcer medications [1]. Group 4: Corporate Mission and Strategy - The company is committed to continuously researching, producing, and promoting excellent pharmaceutical products and services to enhance people's quality of life [2]. - It focuses on the research, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, aiming for specialized development and increased R&D investment to strengthen its core competitiveness [2].

Core Viewpoint - Haisen Pharmaceutical (001367.SZ) has been recognized as a "Little Giant" enterprise in the seventh batch of specialized and innovative small and medium-sized enterprises by the Ministry of Industry and Information Technology of China [1] Group 1 - Haisen Pharmaceutical has successfully passed the certification for the seventh batch of specialized and innovative "Little Giant" enterprises [1] - The recognition is part of a broader initiative by the Ministry of Industry and Information Technology to identify and support innovative companies [1]

每经AI快讯，海森药业（SZ 001367，收盘价：21.73元）12月15日晚间发布公告称，根据国家工业和信 息化部发布的《工业和信息化部关于公布第七批专精特新"小巨人"企业和2025年通过复核专精特新"小 巨人"企业名单的通告》，浙江海森药业股份有限公司（简称"公司"）通过第七批专精特新"小巨人"企 业认定。 公司继被认定为2021年浙江省专精特新中小企业后，本次被认定为国家级专精特新"小巨人"企业，是国 家工业和信息化部对公司技术水平、创新能力、生产制造水平及综合实力等多方面的认可，有利于提高 公司的品牌知名度和在行业内的影响力，对公司整体发展产生积极影响。 2025年1至6月份，海森药业的营业收入构成为：医药制造业占比100.0%。 截至发稿，海森药业市值为33亿元。 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 （记者 王晓波） ...

证券代码：001367 证券简称：海森药业 公告编号：2025-062 浙江海森药业股份有限公司 关于公司被认定为国家级专精特新"小巨人"企业的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 根据国家工业和信息化部发布的《工业和信息化部关于公布第七批专精 特新"小巨人"企业和2025年通过复核专精特新"小巨人"企业名单的通告》， 浙江海森药业股份有限公司（以下简称"公司"）通过第七批专精特新"小 巨人"企业认定。 二、对公司的影响 国家级专精特新"小巨人"企业是工业和信息化部为贯彻落实中共中央办公 厅、国务院办公厅《关于促进中小企业健康发展的指导意见》有关要求，经各省 级主管部门通过组织报送、专家评审及社会公示等流程而评选产生的专注于细分 市场、创新能力强、市场占有率高、掌握核心关键技术、质量效益优的排头兵企 业。 公司继被认定为 2021 年浙江省专精特新中小企业后，本次被认定为国家级 专精特新"小巨人"企业，是国家工业和信息化部对公司技术水平、创新能力、 生产制造水平及综合实力等多方面的认可，有利于提高公司的品牌知名度和在行 业内的影响 ...

海森药业（001367）(001367.SZ)公告，公司通过第七批专精特新"小巨人"企业认定。 ...

Group 1 - Meilixin plans to raise no more than 1.2 billion yuan for semiconductor equipment precision components, communication and automotive parts projects, and to supplement working capital [2] - Olin Bio has prepaid corporate income tax totaling 4.2001 million yuan, with no penalties from tax authorities [3] - Haisen Pharmaceutical's directors and executives plan to reduce their holdings by no more than 124,300 shares, accounting for 0.0816% of the total share capital [4] Group 2 - Aibulu intends to sell 47.4% and 31.6% stakes in its subsidiary Jinque Agriculture for a total of 12.3914 million yuan [5] - Chaoying Electronics plans to increase its Thai subsidiary's capital by 100 million USD for AI high-end PCB expansion [6] - Bona Film Group states that the box office revenue for "Avatar 3" is difficult to predict and the investment return rights are low [7] Group 3 - Junya Technology's PCB products for humanoid robots contribute less than 0.05% to its revenue [9] - Aerospace Electromechanical confirms that its main business does not involve commercial aerospace [10] - Deyi Culture's major shareholder plans to reduce holdings by no more than 2% of shares [11] Group 4 - China National Materials International signed a 2.7 billion yuan engineering contract for a molybdenum mining project [12] - Weiguang Bio plans to sign a 1.13 billion yuan technology cooperation contract for blood products [13] - Suhao Huihong intends to swap assets with its controlling shareholder for a 2.33% stake in Zijin Property Insurance [14] Group 5 - Haike Xinyuan's employee strategic placement plan intends to reduce holdings by no more than 2.5% of shares [15][16] - Taihao Technology's vice president resigns for personal reasons [17] - Huazhu Gaoke plans to establish a joint venture for 3D printing services with a total investment of 100 million yuan [18] Group 6 - Hubei Energy's November power generation was 2.617 billion kWh, a decrease of 17.94% year-on-year [19] - Dong'a Ejiao plans to repurchase shares worth 100 million to 200 million yuan for capital reduction [20] - Longjiang Transportation's shareholder reduced holdings by 1.2% [21] Group 7 - Feilu Co. plans to reduce holdings by no more than 1.02% of shares [22] - Zhongwei Electronics is planning a change in control, leading to a temporary stock suspension [23] - Zhongheng Group's subsidiary received approval for clinical trials of a new cancer drug [24] Group 8 - Guanzhong Ecology's controlling shareholder changed to Deep Blue Financial Whale [25] - Shennong Seed Industry is transferring a 3.8% stake in a subsidiary for 31.9827 million yuan [26] - Sun Cable's major shareholder plans to reduce holdings by no more than 3% of shares [27] Group 9 - Aiwei Electronics' application for issuing convertible bonds has been approved by the Shanghai Stock Exchange [28] - Chongqing Water intends to acquire wastewater treatment projects for 255 million yuan [29] - Boyun New Materials plans to increase its subsidiary's capital by 285 million yuan through debt-to-equity conversion [30] Group 10 - Zhongbai Group is closing unprofitable stores, expecting a loss of approximately 180 million yuan [31] - Changyuan Power's November power generation decreased by 17.88% year-on-year [32]

智通财经APP讯，海森药业(001367.SZ)发布公告，公司部分董事、高级管理人员计划自本公告披露之日 起15个交易日后的3个月内(即2025年12月26日至2026年3月25日)以集中竞价交易方式合计减持公司股份 12.43万股(占公司总股本的0.0816%)。 ...